Company intelligence / Profile preview

AIMM Therapeutics

Amsterdam, Netherlandsaimmtherapeutics.com ↗

Ownership: Private
Employees: ~20
Development stage: Phase 1

Overview

AIMM Therapeutics develops human monoclonal antibodies for cancer and infectious diseases using a proprietary B cell technology. The company has two antibody programs in clinical trials, with additional candidates in preclinical development. Its lead program targets RSV infections and has reached Phase 2 clinical trials. Other pipeline assets address influenza, leukemia, melanoma, Staphylococcus aureus, and undisclosed cancers/infectious diseases. The company was spun out from leading Dutch academic institutions and remains privately held with support from regional life sciences investors.

Therapeutic areas: OncologyInfectious Diseases
Modalities: Monoclonal antibodies (mAbs)
Industry: Biotech

Drug pipeline

1 asset

AT1636

Preclinical

Partnerships

AMC/University of Amsterdam/NKI/Life Sciences Fund Amsterdam

Beyond the preview

Go deeper on AIMM Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AIMM Therapeutics.